Tarsus Pharmaceuticals, Inc. Common Stock Earnings Dividend

Tarsus Pharmaceuticals, Inc. Common Stock’s revenue jumped 69.41% since last year same period to $173.91Mn in the Q2 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated 7.32% jump in its revenue since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s net profit jumped 8.8% since last year same period to $-18.55Mn in the Q2 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated -166.27% fall in its net profits since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 46.16% since last year same period to -10.67% in the Q2 2026. On a quarterly growth basis, Tarsus Pharmaceuticals, Inc. Common Stock has generated -148.11% fall in its net profit margins since last 3-months.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 50% jump from last quarter’s estimates.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.21.

Tarsus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 10.42% since last year same period to -0.43 in the Q2 2026. This indicates that the Tarsus Pharmaceuticals, Inc. Common Stock has generated 10.42% annual rate of jump in its earning per share (EPS) in the last 4 quarters.